Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07353957 · ClinicalTrials.gov registry record · Phase 2
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
A Phase 2 study of Lung Cancer - Non Small Cell Squamous and Lung Cancer - Non Small Cell Non-Squamous, sponsored by Merus B.V..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 3
- Study locations
NCT07353957: Recruiting Phase 2 study of Lung Cancer - Non Small Cell Squamous and Lung Cancer - Non Small Cell Non-Squamous, sponsored by Merus B.V..
NCT07353957 is a Phase 2 study of Lung Cancer - Non Small Cell Squamous and Lung Cancer - Non Small Cell Non-Squamous that is actively recruiting participants, run by Merus B.V.. The registered enrollment target is 180 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07353957, a Phase 2 study of Lung Cancer - Non Small Cell Squamous and Lung Cancer - Non Small Cell Non-Squamous, is actively recruiting participants, sponsored by Merus B.V..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 3
- Study locations
Study Summary
The study will test the efficacy and safety of petosemtamab in combination with Pembrolizumab in first line patients with squamous non-small cell lung cancer and non-squamous non-small cell lung cancer.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Petosemtamab + Pembrolizumab
Study Locations (3)
Tennessee
- Tennessee Site 2 - Chattanooga
- Tennessee Site 1 - Nashville
Virginia
- Virginia Site 1 - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-12-31 |
| Est. Completion | 2031-02-27 |
| Phase | Phase 2 |
What NCT07353957 shows while recruiting
NCT07353957 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher).
The record links to 2 conditions, with Lung Cancer - Non Small Cell Squamous appearing as the primary indexed condition, and to 1 intervention - of which Petosemtamab + Pembrolizumab is the first listed.
NCT07353957 reports a single indexed study location in Tennessee, Virginia.
Frequently Asked Questions
What is clinical trial NCT07353957 about?
NCT07353957 is a clinical study titled "Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer". The study will test the efficacy and safety of petosemtamab in combination with Pembrolizumab in first line patients with squamous non-small cell lung cancer and non-squamous non-small cell lung cancer.
What is the current status of trial NCT07353957?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2025-12-31. Estimated completion is 2031-02-27.
What conditions does trial NCT07353957 study?
This clinical trial studies the following conditions: Lung Cancer - Non Small Cell Squamous, Lung Cancer - Non Small Cell Non-Squamous.
What interventions are being tested in trial NCT07353957?
The interventions under investigation include: Petosemtamab + Pembrolizumab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07353957?
This trial is sponsored by Merus B.V., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07353957 being conducted?
This trial has 3 study locations across Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer - Non Small Cell Squamous
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07353957's enrollment target sits among peer trials
180 365th of 2000 higher than 1,611 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI